H.C. Wainwright analyst Edward White initiated coverage of Aura Biosciences with a Buy rating and $21 price target. Aura is a clinical-stage oncology company focused on developing its virus-like drug conjugate technology platform to treat tumors with high unmet needs in ocular and urologic oncology, the analyst tells investors in a research note. The firm says belzupacap sarotalocan, the company’s lead candidate, has promise to be a vision- and organ-sparing therapy.